Valeant Pharma's (VRX) Proposed Credit Amendment Will Improve Liquidity Position - Moody's

August 10, 2016 10:58 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Moody's Investors Service commented that a proposed amendment to Valeant Pharmaceutical International Inc.'s (NYSE: VRX) credit agreement will improve its liquidity position due to increased cushion under financial maintenance covenants. There is no impact on Valeant's ratings including the B2 Corporate Family Rating or the negative rating outlook.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Credit Ratings

Related Entities

Moody's Investors Service

Add Your Comment